Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

26.7K
Overview
26.7K
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

293
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
293
Cross-reactivity00:42

Cross-reactivity

28.8K
Overview
28.8K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.8K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ozone alters the allergenicity of Ambrosia artemisiifolia pollen in a dose-dependent manner.

Environment international·2026
Same author

Multi-country IgE reactivity determination of isoforms of the <i>Blomia tropicalis</i> mite allergen Blo t 2 revealed a potential biomarker of asthma severity.

Frontiers in immunology·2026
Same author

Maternal-infant immune signatures in infants at risk for SARS-CoV-2-associated neurodevelopmental disorders.

Communications biology·2026
Same author

Engineering Chimeric Hypoallergens for Safer and More Effective House Dust Mite Allergy Vaccines.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2025
Same author

Conformational plasticity of β-rich proteins: Molecular insights into stability, dynamics, and functional adaptation of Bet v 1-like proteins.

International journal of biological macromolecules·2025
Same author

Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG<sub>1</sub> Instead of IgG<sub>4</sub>.

Allergy·2025
Same journal

Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.

Immunotherapy·2026
Same journal

Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapy.

Immunotherapy·2026
Same journal

CAR cellular therapies for acute myeloid leukemia: current landscape and future directions.

Immunotherapy·2026
Same journal

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.

Immunotherapy·2026
Same journal

Exploring global research trends in sublingual immunotherapy of allergic rhinitis: a comprehensive bibliometric analysis.

Immunotherapy·2026
Same journal

Autoimmune encephalitis and axonal polyradiculoneuropathy following therapy with adalimumab and secukinumab: a case report and literature review.

Immunotherapy·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
06:34

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma

Published on: June 4, 2017

9.1K

Recombinant allergens for pollen immunotherapy.

Michael Wallner1, Ulrike Pichler, Fatima Ferreira

  • 1Christian Doppler Laboratory for Allergy Diagnosis & Therapy, Department of Molecular Biology, University of Salzburg, Hellbrunnerstr. 34, A-5020 Salzburg, Austria.

Immunotherapy
|November 29, 2013
PubMed
Summary
This summary is machine-generated.

Specific immunotherapy using recombinant allergens offers a potentially curative treatment for allergies. Engineered hypoallergenic molecules enhance safety and efficacy for pollen allergies, improving upon traditional extract-based methods.

More Related Videos

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.9K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

10.0K

Related Experiment Videos

Last Updated: May 5, 2026

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
06:34

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma

Published on: June 4, 2017

9.1K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.9K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

10.0K

Area of Science:

  • Allergy and immunology
  • Biotechnology
  • Vaccine development

Background:

  • Specific immunotherapy (IT) is the only potentially curative treatment for allergic diseases.
  • Current IT uses allergen extracts, which are heterogeneous mixtures with potential safety concerns.
  • Recombinant allergen technologies offer a promising alternative to traditional extracts.

Purpose of the Study:

  • To review recombinant technologies for producing allergy therapeutics, focusing on pollen allergies.
  • To discuss strategies for modulating recombinant allergen properties to improve safety and efficacy.
  • To summarize recent clinical studies and ongoing investigations in recombinant allergen-based treatments.

Main Methods:

  • Focus on recombinant DNA technology to produce allergen derivatives.
  • Engineering hypoallergenic molecules with reduced IgE-binding and enhanced immunogenicity.
  • Review of animal models and clinical studies evaluating recombinant wild-type allergens and hypoallergens.

Main Results:

  • Recombinant allergen derivatives can be engineered to reduce IgE-binding, improving safety.
  • Hypoallergenic molecules demonstrate inherent antiallergic properties in preclinical models.
  • Clinical studies show successful use of recombinant allergens and hypoallergens, with novel treatments in trials.

Conclusions:

  • Recombinant technologies provide a safer and potentially more effective approach to allergy immunotherapy.
  • Engineering allergen properties is key to developing next-generation allergy vaccines.
  • Ongoing clinical trials are exploring advanced recombinant treatments for prevalent pollen allergies.